Covariability of selected amino acid positions for HIV type 1 subtypes C and B.

We studied covariability of selected amino acid positions in globally dominant HIV-1 subtype C viruses. The analyzed sequences spanned the V3 loop, Gag p17, Gag p24, and five CTL epitope-rich regions in Gag, Nef, and Tat. The corresponding regions in HIV-1 subtype B were also evaluated. The analyses identified a great number of covarying pairs and triples of sites in the HIV-1B V3 loop (173 site pairs, 242 site triples). Several of these interactions were found in the earlier studies [e.g., the V3 loop covariability analyses by Korber et al. (Proc Natl Acad Sci USA 1993;90:7176-7180) and Bickel et al. (AIDS Res Hum Retroviruses 1996;12:1401-1411)] and have known biological significance. However, generally these key covarying sites did not covary in the HIV-1C V3 loop (total 17 covarying site pairs), suggesting that the V3 loop may have subtype differences in functional or structural operating characteristics. Covariability of positions 309 and 312 was observed in the immunodominant region HIV-1C Gag 291-320 but no covariability was found in the corresponding region of HIV-1B, and vice versa for Nef 122-141; these findings may reflect subtype-specific covariability within immunologically relevant regions. Gag p17 exhibited greater covariability and less diversity for HIV-1B than HIV-1C, raising the hypothesis that Gag p17 is highly immunodominant in HIV-1B and is especially important for HIV-1B vaccines. Information on covariability should be better exploited in assessments of HIV-1 diversity and how to surmount it with vaccine design.

[1]  M. Essex.  Human immunodeficiency viruses in the developing world. , 1999, Advances in virus research.

[2]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[3]  D. Robertson,et al.  Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. , 2001, AIDS research and human retroviruses.

[4]  C. Gray,et al.  CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs. , 2007, AIDS research and human retroviruses.

[5]  B. Chesebro,et al.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism , 1992, Journal of virology.

[6]  G. Nabel.  Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.

[7]  G. Shaw,et al.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo , 1992, Journal of virology.

[8]  L. A. Goodman,et al.  Measures of association for cross classifications , 1979 .

[9]  P. Sharp,et al.  A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[10]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[11]  Peter B Gilbert,et al.  Two‐Sample Tests for Comparing Intra‐Individual Genetic Sequence Diversity between Populations , 2005, Biometrics.

[12]  J. Esparza,et al.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.

[13]  D. Davis,et al.  Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. , 1990, The Journal of general virology.

[14]  D. Trono,et al.  The Nef protein of primate lentiviruses , 1999, Reviews in Medical Virology.

[15]  K. Boulez,et al.  The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV‐1 shows pronounced helical character in solution , 1995, FEBS letters.

[16]  T. Ndung’u,et al.  Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. , 2000, Virology.

[17]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[18]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[19]  E. Rosenberg,et al.  Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children , 2000, Journal of Virology.

[20]  B S Weir,et al.  Testing Hypotheses about Linkage Disequilibrium with Multiple Alleles. , 1978, Genetics.

[21]  Bruce S. Weir.  Genetic Data Analysis , 1990 .

[22]  Bette Korber,et al.  T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. , 2003, AIDS research and human retroviruses.

[23]  Winston A Hide,et al.  Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. , 2001, AIDS research and human retroviruses.

[24]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[25]  J. Goudsmit,et al.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity , 1992, Journal of virology.

[26]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[27]  Brian T. Foley,et al.  Numbering Positions in HIV Relative to HXB 2 CG , 1999 .

[28]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[29]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[30]  N. Goldman,et al.  Codon-substitution models for heterogeneous selection pressure at amino acid sites. , 2000, Genetics.

[31]  M. Mulligan,et al.  Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma , 2002, Journal of Virology.

[32]  D. Trono,et al.  A Structure-function Analysis of the Nef Protein of Primate Lentiviruses , 2000 .

[33]  Celia A Schiffer,et al.  Covariation of amino acid positions in HIV-1 protease. , 2003, Virology.

[34]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[35]  V. DeGruttola,et al.  The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.

[36]  Sergei L. Kosakovsky Pond,et al.  Not so different after all: a comparison of methods for detecting amino acid sites under selection. , 2005, Molecular biology and evolution.

[37]  B. Korber,et al.  Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. , 1999, AIDS research and human retroviruses.

[38]  Neff Walker,et al.  Estimated Global Distribution and Regional Spread of HIV‐1 Genetic Subtypes in the Year 2000 , 2002, Journal of acquired immune deficiency syndromes.

[39]  M. P. Cummings.  PHYLIP (Phylogeny Inference Package) , 2004 .

[40]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[41]  Nicole Frahma,et al.  HIV Molecular Immunology 2005 , 2006 .

[42]  A. Lapedes,et al.  Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Graham.  Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[44]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[45]  F. Vannberg,et al.  Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.

[46]  R A Olshen,et al.  Covariability of V3 loop amino acids. , 1996, AIDS research and human retroviruses.

[47]  K. Lole,et al.  Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination , 1999, Journal of Virology.

[48]  W. G. Hill,et al.  Tests for association of gene frequencies at several loci in random mating diploid populations. , 1975, Biometrics.

[49]  F. Vannberg,et al.  Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design , 2001 .

[50]  Steven Wolinsky,et al.  Simian-Human Immunodeficiency Virus Escape from Cytotoxic T-Lymphocyte Recognition at a Structurally Constrained Epitope , 2003, Journal of Virology.